BC, FAANP, explains how a fellowship program sets the tone for how to transition nurse practitioners to oncology.

Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says ...

Panelists discuss how dose modifications for ALK inhibitors can significantly improve quality-of-life issues such as brain ...

Ronald Bleday, MD, explained that a model to reduce opioid use in patients after colorectal surgery relies on nurses familiar with the relevant surgeries.

The FDA has granted accelerated approval to dordaviprone for use in adult and pediatric patients with H3 K27M-mutated diffuse midline glioma.

Panelists discuss that shifting talquetamab dosing from weekly to every 2 weeks improves response durability and patient ...

Panelists discuss that the phase 2 TALISMAN trial evaluated prophylactic strategies to prevent severe oral toxicities with talquetamab, highlighting the importance of early patient education, ...

For patients with HR-positive breast cancer, adverse effects vary by CDK4/6 inhibitor, says Courtney Moore, APRN, FNP-C, OCN.

Cancer survivors, particularly men, in physically demanding jobs often face pressure to keep working during treatment, says ...

C, CNS, explained that understanding a patient’s emotional needs can help educate them on treatment adherence.

Hope S. Rugo, MD, FASCO, outlined the top considerations for nurses managing toxicities related to PI3K and AKT inhibitors in ...